There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intra-Cellular Therapies (ITCI – Research Report), Penumbra (PEN – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report) with bullish sentiments.
Intra-Cellular Therapies (ITCI)
In a report released today, Ami Fadia from Needham reiterated a Buy rating on Intra-Cellular Therapies, with a price target of $82.00. The company’s shares closed last Thursday at $71.93, close to its 52-week high of $76.11.
According to TipRanks.com, Fadia is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intra-Cellular Therapies with a $81.90 average price target, which is a 16.4% upside from current levels. In a report issued on February 8, J.P. Morgan also maintained a Buy rating on the stock with a $75.00 price target.
See today’s best-performing stocks on TipRanks >>
Penumbra (PEN)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Penumbra, with a price target of $289.00. The company’s shares closed last Thursday at $262.68.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
Currently, the analyst consensus on Penumbra is a Strong Buy with an average price target of $291.00.
BioMarin Pharmaceutical (BMRN)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $100.00. The company’s shares closed last Thursday at $89.97.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $106.14 average price target, representing a 18.9% upside. In a report issued on February 16, Jefferies also maintained a Buy rating on the stock with a $133.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ITCI:
- Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
- Intra-Cellular Therapies Business and Clinical Progress Update
- Notable companies reporting before tomorrow’s open
- Intra-Cellular price target raised to $82 from $76 at Mizuho
- Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
